Biodexa Pharmaceuticals Plc(BDRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.9M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BDRX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Biodexa Pharmaceuticals Plc (BDRX), a Healthcare sector company. BDRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.9m in revenue and is scored on the micro-cap board instead. Top institutional holders of BDRX by reported 13-F value include ARMISTICE CAPITAL, GAMMA Investing, Allied Private Wealth, based on the most recent SEC filings. BDRX trades on the Nasdaq exchange and files with the SEC under CIK 1643918. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biodexa Pharmaceuticals Plc directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Total Assets
+23.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $381.0K -45.5% | $699.0K +20.9% | $578.0K +68.5% | $343.0K |
| Total Assets | $18.2M +23.0% | $14.8M +40.2% | $10.5M +90.8% | $5.5M -57.2% | $12.9M +31.5% | $9.8M |
AI Insight: BDRX Financial Trends
Insufficient financial data to assess operational trends; only equity figures available across eight quarters.
• Equity grew from $7M in Q2 2022 to $11M in Q4 2025, a 57% increase over 3.5 years.
⚠ Revenue, net income, operating income, operating cash flow, and debt all missing—unable to assess profitability, cash generation, or leverage trends.
AI Insight: BDRX Ratio Trends
Data unavailable: all financial ratios are missing across the entire dataset.
• No operating margin, net profit margin, ROE, ROA, ROIC, or debt-to-equity data present in the table from Q2 2022 through Q4 2025.
⚠ Unable to assess profitability trends, return on capital, or leverage metrics. Data gap prevents trend analysis.
Get alerted when BDRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Biodexa Pharmaceuticals Plc including:
Top Institutional Holders of BDRX
ARMISTICE CAPITAL, LLC
$43.1K14,809 shGAMMA Investing LLC
$3.5K1,203 shAllied Private Wealth LLC
$1.3K489 shSBI Securities Co., Ltd.
$84.0029 shUBS Group AG
$73.0025 shHilton Head Capital Partners, LLC
$17.006 shCaitong International Asset Management Co., Ltd
$15.005 shRHUMBLINE ADVISERS
$8.003 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $43.1K | 14,809 |
| GAMMA Investing LLC | $3.5K | 1,203 |
| Allied Private Wealth LLC | $1.3K | 489 |
| SBI Securities Co., Ltd. | $84.00 | 29 |
| UBS Group AG | $73.00 | 25 |
| Hilton Head Capital Partners, LLC | $17.00 | 6 |
| Caitong International Asset Management Co., Ltd | $15.00 | 5 |
| RHUMBLINE ADVISERS | $8.00 | 3 |
More Healthcare Companies
View all Healthcare →Put BDRX on your watchlist
Track score changes the day Biodexa Pharmaceuticals Plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BDRX a good stock to buy?
13F Pro's AI-powered analysis of Biodexa Pharmaceuticals Plc (BDRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BDRX are available on the BDRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BDRX is classified as a large company.
Which hedge funds own BDRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BDRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Biodexa Pharmaceuticals Plc's investment landscape.